Jakafi, Jakavi(ruxolitinib)
Jakafi, Jakavi, Opzelura (ruxolitinib) is a small molecule pharmaceutical. Ruxolitinib was first approved as Jakafi on 2011-11-16. It is used to treat polycythemia vera and primary myelofibrosis in the USA. It has been approved in Europe to treat graft vs host disease, myeloproliferative disorders, polycythemia vera, and vitiligo. The pharmaceutical is active against tyrosine-protein kinase JAK1 and tyrosine-protein kinase JAK2. In addition, it is known to target tyrosine-protein kinase JAK3 and non-receptor tyrosine-protein kinase TYK2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Jakafi, Opzelura
Drug Products
FDA
EMA
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| polycythemia vera | — | D011087 | D45 |
| primary myelofibrosis | — | D055728 | D47.4 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
RUXOLITINIB PHOSPHATE, JAKAFI, INCYTE CORP | |||
| 2029-03-22 | PED | ||
| 2028-09-22 | ODE-373 | ||
| 2026-11-24 | PED | ||
| 2026-06-19 | PED | ||
| 2026-05-24 | ODE-238 | ||
| 2025-12-19 | M-285 | ||
| 2025-03-22 | PED | ||
| 2024-09-22 | I-872 | ||
RUXOLITINIB PHOSPHATE, OPZELURA, INCYTE CORP | |||
| 2026-01-18 | PED | ||
| 2025-07-18 | I-896 | ||
| 2025-03-21 | PED | ||
| 2024-09-21 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Ruxolitinib Phosphate, Opzelura, Incyte Corp | |||
| 11602536 | 2041-05-05 | U-3550 | |
| 11510923 | 2040-09-04 | U-3505 | |
| 11590137 | 2040-09-04 | U-3505 | |
| 11590138 | 2040-06-10 | U-3551 | |
| 10758543 | 2031-05-20 | DP | |
| 10869870 | 2031-05-20 | U-3229, U-3404 | |
| 11219624 | 2031-05-20 | DP | U-3229 |
| 11571425 | 2031-05-20 | DP | |
| 11590136 | 2031-05-20 | U-3229, U-3404 | |
| 10610530 | 2028-06-12 | U-3229, U-3404 | |
| 9974790 | 2026-12-12 | U-3229, U-3404 | |
| 10639310 | 2026-12-12 | U-3229 | |
| Ruxolitinib Phosphate, Jakafi, Incyte Corp | |||
| 8722693 | 2028-06-12 | DS, DP | |
| 8822481 | 2028-06-12 | U-1573, U-3226, U-3227, U-3228, U-3229, U-3230, U-3404 | |
| 8829013 | 2028-06-12 | U-1201, U-1622, U-3227, U-3228 | |
| 10016429 | 2028-06-12 | U-3226, U-3230 | |
| 7598257 | 2027-12-24 | DS, DP | U-3227, U-3228 |
| 8415362 | 2027-12-24 | DS, DP | |
| 9079912 | 2026-12-12 | U-3226, U-3227, U-3228, U-3229, U-3230, U-3404 | |
| 9814722 | 2026-12-12 | U-3226, U-3230 | |
HCPCS
No data
Clinical
Clinical Trials
440 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary myelofibrosis | D055728 | — | D47.4 | 45 | 69 | 17 | 3 | 12 | 126 |
| Polycythemia vera | D011087 | — | D45 | 11 | 25 | 14 | 1 | 11 | 57 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | 10 | 22 | 11 | 1 | 9 | 49 |
| Essential thrombocythemia | D013920 | — | D47.3 | 14 | 24 | 9 | 1 | 3 | 44 |
| Graft vs host disease | D006086 | — | D89.81 | 8 | 24 | 6 | 3 | 5 | 43 |
| Thrombocytosis | D013922 | — | D75.83 | 10 | 22 | 8 | 1 | 3 | 38 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 11 | 14 | — | 1 | 1 | 23 |
| Eczema | D004485 | — | L30.9 | 4 | 5 | 7 | 1 | 2 | 19 |
| Bronchiolitis obliterans syndrome | D000092122 | — | D89.811 | 4 | 11 | 2 | 1 | — | 18 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 4 | 4 | 6 | 1 | 2 | 17 |
Show 15 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloproliferative disorders | D009196 | — | D47.1 | 20 | 30 | 4 | — | 1 | 45 |
| Leukemia | D007938 | — | C95 | 22 | 25 | 3 | — | 1 | 36 |
| Covid-19 | D000086382 | — | U07.1 | 2 | 11 | 4 | — | 8 | 22 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 10 | 12 | 2 | — | 1 | 20 |
| Myelodysplastic syndromes | D009190 | — | D46 | 10 | 12 | 1 | — | — | 20 |
| Vitiligo | D014820 | EFO_0004208 | L80 | — | 7 | 4 | — | 1 | 11 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 6 | 5 | 1 | — | — | 10 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 3 | 7 | 1 | — | — | 9 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 4 | 3 | 2 | — | — | 8 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | 3 | 1 | — | 2 | 5 |
Show 17 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 12 | 15 | — | — | 1 | 22 |
| Myeloid leukemia | D007951 | — | C92 | 7 | 10 | — | — | 1 | 14 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 7 | 7 | — | — | — | 12 |
| Lymphoid leukemia | D007945 | — | C91 | 7 | 5 | — | — | 1 | 11 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 6 | 8 | — | — | — | 11 |
| Recurrence | D012008 | — | — | 7 | 4 | — | — | 1 | 10 |
| Hematologic neoplasms | D019337 | — | — | 5 | 6 | — | — | — | 10 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 5 | 6 | — | — | — | 9 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 5 | 6 | — | — | — | 9 |
| Multiple myeloma | D009101 | — | C90.0 | 7 | 3 | — | — | — | 8 |
Show 111 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | — | — | 2 | — | — | — | — | 2 |
| Philadelphia chromosome | D010677 | — | — | 1 | — | — | — | — | 1 |
| Residual neoplasm | D018365 | — | — | 1 | — | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | — | — | — | — | 1 |
| Serous cystadenocarcinoma | D018284 | — | — | 1 | — | — | — | — | 1 |
| Clear cell adenocarcinoma | D018262 | — | — | 1 | — | — | — | — | 1 |
| Carcinosarcoma | D002296 | — | — | 1 | — | — | — | — | 1 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 1 | — | — | — | — | 1 |
| Immunoblastic lymphadenopathy | D007119 | EFO_1001350 | C86.5 | 1 | — | — | — | — | 1 |
| Mycosis fungoides | D009182 | — | C84.0 | 1 | — | — | — | — | 1 |
Show 13 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy rate | D018873 | — | — | — | — | — | — | 2 | 2 |
| Acute disease | D000208 | — | — | — | — | — | — | 1 | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
Show 26 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ruxolitinib |
| INN | ruxolitinib |
| Description | Ruxolitinib is a pyrazole substituted at position 1 by a 2-cyano-1-cyclopentylethyl group and at position 3 by a pyrrolo[2,3-d]pyrimidin-4-yl group. Used as the phosphate salt for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. It has a role as an antineoplastic agent and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It is a nitrile, a pyrrolopyrimidine and a member of pyrazoles. |
| Classification | Small molecule |
| Drug class | deuterated compounds; tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1 |
Identifiers
| PDB | — |
| CAS-ID | 941678-49-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1789941 |
| ChEBI ID | 66919 |
| PubChem CID | 25126798 |
| DrugBank | DB08877 |
| UNII ID | 82S8X8XX8H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
JAK3
JAK3
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Jakavi – Incyte
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Jakavi – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Jakafi – Incyte
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Opzelura – Incyte
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,683 documents
View more details
Safety
Black-box Warning
Black-box warning for: Opzelura
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
69,051 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use